Results 41 to 50 of about 1,044,683 (223)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration [PDF]

Cancer Chemotherapy and Pharmacology, 2015
nab-paclitaxel demonstrates improved clinical efficacy compared with conventional Cremophor EL (CrEL)-paclitaxel in multiple tumor types. This study explored the distinctions in drug distribution between nab-paclitaxel and CrEL-paclitaxel and the underlying mechanisms.Uptake and transcytosis of paclitaxel were analyzed by vascular permeability assay ...
Chen, Nianhang, Brachmann, Carrie, Liu, Xiping, Pierce, Daniel W., Dey, Joyoti, Kerwin, William S., Li, Yan, Zhou, Simon, Hou, Shihe, Carleton, Michael, Klinghoffer, Richard A., Palmisano, Maria, Chopra, Rajesh   +12 more
openaire   +2 more sources

Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain

Advanced Science, EarlyView.
Tissue incision induces CXCL5 release, which activates neuronal CXCR2 on incision‐innervating sensory neurons. Neuronal CXCR2 couples with TRPA1 to drive mechanical pain and engages p38 MAPK signaling to upregulate TRPV1 and promote heat pain. Targeted Cxcr2 knockdown relieves incisional pain while preserving CXCR2‐dependent neutrophil responses ...
Yushuang Pan, Peiyi Li, Yufeng Chen, Zishan Dong, Yuanyuan Li, Boyu Liu, Yan Tai, Chuan Wang, Jianqiao Fang, Chengyu Yin, Boyi Liu   +10 more
wiley   +1 more source

Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen, Yangyi Wang, Tingting Li, Changqing Guo, Zhe Xie, Zhixian Zhang, Xinghua Han, Wei Wang, Jian Wang, Xiaopeng Ma, Yuanzeng Min   +10 more
wiley   +1 more source

Impact of tislelizumab combined with albumin-bound paclitaxel and carboplatin on intestinal flora and gastrointestinal toxicities in advanced lung cancer

Pakistan Journal of Pharmaceutical Sciences
To evaluate the impact of tislelizumab combined with albumin-bound paclitaxel and carboplatin on intestinal flora and gastrointestinal toxicities in advanced lung cancer patients.
Kai Feng, Tianwei Liu, Ruihua Ren, Yanan Zhao, Haiyang Li, Jiyun Wang   +5 more
doaj   +1 more source

A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer [PDF]

, 2015
Platinum plus etoposide is the standard therapy for extensive-stage small cell lung cancer (ES-SCLC) and is associated with significant myelosuppression.
Grilley-Olson, J. E., Keedy, V. L., Sandler, A., Moore, D. T., Socinski, M. A., Stinchcombe, T. E.   +5 more
core   +1 more source

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer‐Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy

Advanced Science, EarlyView.
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo, Yang Zhao, Xianle Rong, Xingyu Chen, Xiao Wang, Tianyi Liu, Yunfei Xie, Yushu Zou, Pingsen Zhao, Qiang Liu, Fuping You   +10 more
wiley   +1 more source

Asymmetric Structure‐Driven Functional Synergy: A Multistimuli‐Activated Janus Nanomotor for Self‐Amplifying NO Cascade Therapy

Advanced Science, EarlyView.
The Janus nanomotors leverage an “asymmetric structure‐driven functional synergy” strategy to orchestrate spatiotemporally coordinated catalytic functions, in situ self‐amplifying NO generation, and deep tumor penetration, thereby enabling controllable, sustained, and uniform NO generation within the tumor microenvironment.
Chengcheng Li, Yu Zhang, Yu Chen, Lingyun He, Xian Shen, Weijian Sun, Hongbo Zhang   +6 more
wiley   +1 more source

3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate

Advanced Science, EarlyView.
The blood–brain–tumor barrier (BBTB) penetration by anticancer drugs and their effects on glioblastoma (GBM) is assessed using 3D bioprinted‐spheroids. Anticancer drug‐induced U‐87 MG cell death is quantified through in situ imaging of spheroids using a cancer cell death probe. The Ru compound, a partial P‐gp substrate, induces greater tumor‐cell death
Hyunjung Lee, Chan Ho Jeon, Doyun Kim, Minjae Lee, Minji Kwon, Joon Myong Song   +5 more
wiley   +1 more source

Clinical development of Abraxane, albumin-bound paclitaxel

Drug Delivery System, 2009
Abraxaneは，Cremophor ELおよびエタノールを溶媒として使用せず，ヒト血清アルブミンを添加物とした均一なナノ粒子製剤である．Cremophor ELを含まないことから前投薬を必要とせず，また，Taxolより短時間で高用量のpaclitaxel投与が可能となった．
openaire   +1 more source

Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trialResearch in context

EClinicalMedicine, 2023
Summary: Background: Sintilimab is an antibody against programmed cell death protein 1. We assessed the efficacy and safety of sintilimab plus albumin-bound (nab)-paclitaxel for the treatment of recurrent or metastatic cervical cancer.
Yin Wang, Jing Zhao, Haixi Liang, Junxiu Liu, Shenjiao Huang, Guorong Zou, Xin Huang, Chunyan Lan   +7 more
doaj   +1 more source